<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04862767</url>
  </required_header>
  <id_info>
    <org_study_id>ATB-301-001</org_study_id>
    <nct_id>NCT04862767</nct_id>
  </id_info>
  <brief_title>TASO-001 in Combination With Recombinant Interleukin-2(Aldesleukin) in Advanced or Metastatic Solid Tumor</brief_title>
  <official_title>Multi-center, Open Label, Phase Ib Clinical Trial to Evaluate Safety, Tolerance and Efficacy of TASO(TGF-β2 Targeting Anti-sense Oligonucleotide)-001 in Combination With Recombinant Interleukin-2 in Advanced or Metastatic Solid Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Autotelicbio</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Autotelicbio</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate safety, tolerance and efficacy of TASO(TGF-β2 targeting anti-sense&#xD;
      oligonucleotide)-001 in combination with recombinant interleukin-2(Aldesleukin) in advanced&#xD;
      or metastatic solid tumor and to find appropriate dose for phase 2 clinical trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial is conducted by dividing into two cohorts according to the dose of the&#xD;
      test drug, starting with Cohort 1, and confirming whether DLT occurs until 14 days after the&#xD;
      2nd cycle of the test drug administration and proceed with Cohort 2 after discussion by DMC.&#xD;
      Recruitment of each cohort is applied with a 3+3 design.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 9, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>3+3 design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of MTD (Tolerability)</measure>
    <time_frame>4weeks(DLT)</time_frame>
    <description>MTD and RP2D are determined</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR(objective response rate)</measure>
    <time_frame>every 8 weeks, and up to 14 days after the last dose of TASO-001</time_frame>
    <description>In case the best overall response expressed as CR or PR by RECIST v1.1 and iRECIST, the rate of subjects should be presented for each dose group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR(Disease control rate)</measure>
    <time_frame>every 8 weeks, and up to 14 days after the last dose of TASO-001</time_frame>
    <description>In case the best overall response expressed as CR, PR or SD by RECIST v1.1 and iRECIST, the rate of subjects should be presented for each dose group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DoR(Duration of response)</measure>
    <time_frame>every 8 weeks, and up to 14 days after the last dose of TASO-001</time_frame>
    <description>Median, standard deviation and 95% confidential interval of DoR is estimated by the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS(Progression free survival)</measure>
    <time_frame>every 8 weeks, up to 14 days after the last dose of TASO-001</time_frame>
    <description>: Median, standard deviation and 95% confidential interval of PFS is estimated by the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS(Overall survival)</measure>
    <time_frame>every 8 weeks, up to 14 days after the last dose of TASO-001</time_frame>
    <description>: Median, standard deviation, 95% confidential interval of OS is estimated by Kaplan-Meier method.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>TASO-001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>level 1 of TASO-001 in combination with recombinant IL-2(Aldesleukin)(3+3) next than level 2 or level -1 of TASO-001 in combination with recombinant IL-2(Aldesleukin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TASO-001((TGF-β2 targeting anti-sense oligonucleotide)</intervention_name>
    <description>96 hour continuous infusion</description>
    <arm_group_label>TASO-001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Aldesleukin</intervention_name>
    <description>SC, Bid</description>
    <arm_group_label>TASO-001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults over 19 years old on the day of consent&#xD;
&#xD;
          2. Pathologically confirmed solid cancer&#xD;
&#xD;
          3. Patients with advanced or metastatic solid timour failed or tolerable with standard&#xD;
             therapy.&#xD;
&#xD;
          4. A person who has a tumor lesion that can safely undergo tissue biopsy during&#xD;
             administration of the test drug and can provide tissues stored at the clinical trial&#xD;
             agency or tissue obtained from a tissue biopsy conducted before the first&#xD;
             administration of the test drug&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Those who have been treated with IL-2 or TGF-β inhibitors other than test drugs (e.g.,&#xD;
             anti-sense oligonucleotide, antibody, TGF-b receptor inhibitor)&#xD;
&#xD;
          2. Chemotherapy within 21 days or at least 5 half-lives (whichever is shorter) prior to&#xD;
             first dose of study treatment.&#xD;
&#xD;
          3. Immunotherapy within 2 weeks prior to first dose of study treatment.&#xD;
&#xD;
          4. Major surgery within 4 weeks prior to first dose of study treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Jun, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Autotelicbio</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>hyojeong Seo</last_name>
    <phone>823180818780</phone>
    <email>hjseo@autotelic.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Juneui Park, Ph.D</last_name>
    <phone>823180818780</phone>
    <email>juneui.park@autotelic.co.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Do-youn Oh, M.D., PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 17, 2021</study_first_submitted>
  <study_first_submitted_qc>April 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2021</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autotelicbio</keyword>
  <keyword>TASO</keyword>
  <keyword>ATB-301</keyword>
  <keyword>TGF-β2</keyword>
  <keyword>Anti-sense Oligonucleotide</keyword>
  <keyword>Interleukin-2</keyword>
  <keyword>Aldesleukin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

